# Two phenotypes of Chronic Recurrent Multifocal Osteomyelitis with different patterns of bone involvement

Dita Cebecauerová<sup>1</sup>, Hana Malcová<sup>1</sup>, Veronika Koukolská<sup>2</sup>, Zuzana Kvíčalová<sup>3</sup>, Ondřej Souček<sup>4</sup>, Lukáš Wagenknecht<sup>5</sup>, Jiří Bronský<sup>4</sup>, Zdeněk Šumník<sup>4</sup>, Martin Kynčl<sup>2</sup>, Marek Cebecauer<sup>3</sup> and Rudolf Horváth<sup>1</sup>

<sup>1</sup> Department of Paediatric and Adult Rheumatology, Motol University Hospital , Prague, Czech Republic

<sup>2</sup> Department of Radiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

<sup>3</sup> Department of Biophysical Chemistry, J. Heyrovsky Institute of Physical Chemistry of the Czech Academy of Sciences, Prague, Czech Republic

<sup>4</sup> Department of Pediatrics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

<sup>5</sup> Department of Ortopaedics, Second Faculty of Medicine, Motol University Hospital, Prague, Czech Republic

Corresponding author: Dita Cebecauerova M.D, PhD., dita.cebecauerova@fnmotol.cz

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 1 Abstract

2

Introduction: Chronic Recurrent Multifocal Osteomyelitis (CRMO) is an autoinflammatory bone disorder with predominantly paediatric onset. Children present with multifocal osteolytic lesions accompanied by bone pain and soft tissue swelling. Patients often exhibit extraosseous co-morbidities such as psoriasis, inflammatory bowel disease, and arthritis.

Objectives: Comparison of children with two different phenotypes of CRMO defined by presence or
 absence of extraosseous co-morbidities.

9 Methods: Children diagnosed with CRMO at the Motol University Hospital between 2010-2020 were

10 retrospectively reviewed, and according to the absence or presence of extraosseous manifestations

11 divided into two cohorts – osteolytic CRMO and complex CRMO. The two groups were compared in

12 terms of demographic data, age at disease onset, number and site of bone lesions, laboratory

13 biomarker values, and need of escalation to a second-line therapy

14 **Results**: Thirty-seven children (30 female, 7 male) with confirmed CRMO were included in the analysis.

- The mean age at disease onset was ten years. All but 3 patients presented with multifocal disease. Twenty-three children (62%) had at least one extraosseous manifestation (13 sacroiliitis, 8 inflammatory bowel disease, 6 skin disease [acne, pustulosis, or psoriasis], 7 arthritis). Complex CRMO was associated with a significantly higher ESR rate (p=0.0064) and CRP level (p=0.018). The groups did not differ in number of foci or in age at disease onset. Bone lesion distribution differed between the two groups with significantly more frequent involvement of clavicle (p=0.011) and pelvis (p=0.038) in patients with complex CRMO. Children with complex CRMO more often needed escalation of therapy
- to DMARDs and biologic agents.

Conclusion: Our data suggest that CRMO affecting solely the skeleton has milder course compared to
 complex CRMO with extraskeletal features. Further studies are needed to explore the clinical as well
 as the patient reported outcomes and promote individually tailored therapeutic strategies in both

26 CRMO phenotypes.

### 27 Keywords

Autoinflammatory disease, chronic non-bacterial osteomyelitis, chronic recurrent multifocal
 osteomyelitis, inflammatory bowel disease, sacroiliitis, whole-body magnetic resonance imaging

30

### 31 Introduction

32

33 Chronic Recurrent Multifocal Osteomyelitis (CRMO) is a rare autoinflammatory disorder characterized by sterile bone lesions <sup>1,2</sup>. It is often referred to as a subgroup within Chronic Non-Bacterial 34 Osteomyelitis (CNO). For patients with concomitant acne or pustulosis the acronym SAPHO (Synovitis, 35 acne, pustulosis, hyperostosis, osteitis) is used. CRMO incidence is estimated at 1:250 000<sup>3</sup>; precise 36 37 values remain unknown. However, the number of diagnosed cases has increased lately with improved 38 public and care-provider awareness and better accessibility of whole-body magnetic resonance 39 imaging (WB-MRI)<sup>4,5</sup>. It affects predominantly young girls with peak presentation at age 10 years <sup>6-8</sup>, 40 typically with bone pain accompanied by local warmth and soft tissue swelling. The disease course is 41 recurrent or persistent with a variable number of osteolytic lesions developing over time. The unifocal 42 and persistent form is more common in adult patients <sup>9</sup>. Adults and adolescents often display involvement of clavicle and sternum and have various cutaneous manifestations <sup>9,10</sup>. 43

44 The molecular pathogenesis is not fully understood, but there is a consensus that CRMO is an 45 autoinflammatory disease, characterized by unprovoked spontaneous flares of tissue-specific bone 46 inflammation. The fact that different autoimmune conditions frequently affect pedigrees of CRMO 47 patients emphasizes the role of genetic predispositions. However, specific genetic variants are characterised only in a small proportion of patients <sup>11-14</sup>. Typical examples of monogenic forms of 48 49 osteomyelitis represent Majeed syndrome or DIRA (Deficiency of Interleukin-1 Receptor Antagonist), with an altered IL-1 signalling pathway. Mutations in the coding and regulatory parts of FLBIM1 are 50 51 found in a minority of children with non-syndromic CRMO together with an altered IL-10 signalling 52 pathway<sup>11,12</sup>. These variants are, nevertheless, considered as contributing to rather than as underlying 53 CRMO. At this writing, no other entries for CRMO exist in the Online Mendelian Inheritance in Man 54 database<sup>15</sup>. Clinically, CRMO shares significant overlap with TNF $\alpha$ -related autoimmune conditions such as spondyloarthritis, psoriasis, and inflammatory bowel disease (IBD). Indeed, CRMO and/or 55 56 SAPHO syndrome may, over time, evolve into spondyloarthropathy in some patients <sup>16</sup>. The available 57 data are limited but suggest that aetiopathogenesis of CRMO is complex and that a probably 58 heterogenous genetic background underlies a seemingly uniform phenotype.

59 Recent reports indicate that about half of CRMO patients have associated extraosseous involvement, 60 mostly psoriasis and palmo-plantar pustulosis, IBD, and arthritis. The frequency of particular co-61 morbidities varies significantly among reported cohorts<sup>6,8,9,17,18</sup>. Whilst cutaneous involvement is 62 reported in 10-30% of patients, IBD is diagnosed in a much smaller group (5-13%). Arthritis varies 63 significantly between individual cohorts (6-56%). Evidently, more studies are required better to 64 understand these complex relations between CRMO and associated conditions.

So far, no specific guidelines exist for the treatment of children with CRMO. Therapy response
assessment is complicated by the lack of a definition of disease remission. Based on current treatment
practices, Zhao et al. published consensus treatment plans for CRMO refractory to non-steroidal anti-

68 inflammatory drugs (NSAIDs) <sup>10</sup>. Whereas NSAIDs represent first-line treatment, bisphosphonates are 69 used in case of spinal involvement or NSAIDs failure. Disease-modifying anti-rheumatic drugs 70 (DMARDs) and short-course corticosteroids can be used to escalate therapy; however, disease 71 remission is achieved in fewer patients for whom these approaches are required <sup>6,9,19,20</sup>. Biologic 72 DMARDs, primarily tumour necrosis factor  $\alpha$  inhibitors (TNFi), are the preferred choice in refractory 73 disease or associated conditions, including sacroiliitis or IBD <sup>21,22</sup>.

This study postulated that the two distinct phenotypic manifestations of CRMO – a solely osteolytic form, with only bone involvement, and a complex form, characterised by the presence of extraosseous associated conditions – might differ in clinical and laboratory aspects of disease, and sought to compare cohorts of children with the two forms of CRMO.

78

#### 79 Methods

80 We retrospectively reviewed and analysed a cohort of paediatric CRMO patients diagnosed and 81 treated at Motol University Hospital, Prague, between 2010 and 2020. Only children still followed-up 82 in Motol University Hospital, were included in the study. The diagnosis was based on the typical clinical and radiological findings and in 62% of children was completed by histologic and microbiologic 83 confirmation of chronic non-bacterial osteomyelitis. Bristol criteria<sup>17,23</sup> were applied retrospectively 84 85 to all patients included in the study. The study was approved by the local Ethics Committee (EK 86 1412/20). Written informed consent was obtained from patients or legal guardians before study 87 enrolment. From medical records we collected clinical data, including family history, gender, ethnicity, 88 age of disease onset, first symptoms at manifestation, number and distribution of bone lesions, biopsy 89 results, microbiologic results, spinal involvement, inflammatory and immunological marker values, 90 faecal calprotectin levels, extraosseous disease, and therapy. WB-MRI and X-ray imaging were re-91 assessed by an experienced radiologist. Sacroiliac-joint involvement was diagnosed only when typical 92 oedema of subchondral bone was present.

#### 93 Statistical analysis

94 Fisher's exact test was used to compare the two groups of patients with lesions present and absent at 95 a given site. All datasets (age at onset, number of foci, erythrocyte sedimentation rate [ESR], and 96 serum C-reactive protein [CRP]) were first tested for normality using quantile-quantile plots and the 97 Anderson-Darling test. Number of lesions and age at onset showed normal distributions with equal 98 variance (two-sample F-test). Two-sample unpaired Student's t-testing was used to compare the means between the osteolytic and complex CRMO groups. For ESR and CRP parameters not following 99 100 a normal distribution, means were compared with the two-sample Kolmogorov-Smirnoff test. 101 Statistical analyses were performed using appropriate functions of MATLAB software (Mathworks, 102 Natick, MA).

4

#### 103

### 104 Results

105 Thirty-seven children, 30 girls (81%) and 7 boys (19%), were enrolled in the study (Fig. 1). Their clinical 106 characteristics are summarized in Tab. 1. The initial symptom in most cases was limb pain (51%), 107 followed by back pain (38%). The prevalently affected site was pelvis (59%), followed by femur (49%), 108 tibia (43%), spine (38%), and clavicle (35%). Clavicular swelling as a first sign was present in 2 patients 109 (5%); however, WB-MRI revealed asymptomatic clavicular lesions in 11 more children, with bilateral 110 involvement in 4. Diaphyseal regions were affected in 9 children (24%). In six the lesion laid within the large metaphyseal-diaphyseal region. Solely diaphyseal lesions were confirmed in 4 children (11%). 111 The least involved regions were skull, mandible, and scapula, with involvement in 2 children each. Just 112 113 3 patients (8%) were proven to have a single osteolytic site on WB-MRI. These solitary lesions were in 114 10<sup>th</sup> thoracic vertebra, clavicle, and humerus.

115 Inflammation-marker values were elevated at presentation in most of the patients. ESR and/or CRP 116 were increased in 24 children (65%) at the time of diagnosis, but they did not intercorrelate in all 117 patients, *i.e.*, some children had elevated ESR but not CRP and *vice versa*. Only 5 children had 118 inflammatory-marker values within normal range. ANA were identified in 2 patients (5%). HLA-B27 119 positivity was detected in 6 children (16%), an incidence twice as high as that in a general Central 120 European population <sup>24</sup>.

121 Twenty-five children (68%) had family histories of one or more autoimmune diseases in first- and 122 second-degree relatives (Fig. 2a), most often IBD (6) and psoriasis (3). Twenty-three CRMO patients 123 (62%) had associated extraosseous conditions (Fig. 2b) at the time of diagnosis or developed them 124 during follow-up (1-10 years). These were considered as 'complex CRMO' in this study. Thirteen 125 children (35%) had sacroiliitis (Tab. 1), 7 of them symptomatic. In 6 patients, sacroiliitis remained 126 clinically silent. Bilateral sacroiliitis was more frequent than unilateral and was not associated with 127 HLA-B27 positivity. Only one HLA-B27 positive child had MRI-proved sacroiliitis (Fig. 3). In this patient, 128 sacroiliitis remained asymptomatic despite ongoing inflammation detectable by MRI. On the other 129 hand, 5 out of 6 HLA-B27 positive children had vertebral lesions (Fig. 3). Four children who were 130 treated with bisphosphonates achieved regression of sacroiliitis.

Eight children in our cohort (22%) developed enteropathic CRMO, osteomyelitis associated with IBD. 131 Four had family histories of IBD. Tab. 2 summarizes characteristic features and the sequential course 132 133 of their disease. CRMO preceded IBD in 3 patients and IBD preceded CRMO in 5. The average delay 134 between presentation and manifestation of the associated disorder was 4 years. Two children who 135 initially presented with CRMO and in whom complete remission of bone disease was achieved later 136 developed IBD without relapse of CRMO. Enteropathic CRMO appears to be a specific subtype of the 137 disease with a more severe phenotype. Such children in our study frequently suffered from more than 138 one extraosseous manifestation, including skin disease, sacroiliitis, arthritis, primary sclerosing 139 cholangitis, and uveitis. All children with enteropathic CRMO had elevated faecal calprotectin levels

(Tab. 2). Mild elevation of faecal calprotectin (FCP; up to 250 μg/g) was found in samples from 9 other
 CRMO patients, but they did not progress to IBD, and their FCP levels dropped during follow-up.

142 Arthritis was diagnosed in 7 children (19%); 6 of them had a family history of autoimmune disease. 143 Arthritis primarily but not exclusively adjoined foci of osteomyelitis. Eight patients (22%) developed 144 skin disease including acne (n=3), pustular psoriasis (n=1), palmoplantar pustulosis (n=2), and atopic 145 or unspecified dermatitis (n=3). SAPHO syndrome was diagnosed in 3 individuals (8%) based on severe 146 nodulocystic acne and clavicular involvement with typical imaging findings. All 3 patients had an inflammatory phenotype at the time of diagnosis. Palmoplantar pustulosis occurred as a paradoxical 147 148 effect of TNFi therapy (1x infliximab, 1x adalimumab) in 2 children who initially suffered from IBD and 149 later manifested CRMO. Their skin disease was managed by topical treatment without withdrawal of 150 TNFi therapy. One patient presented with chronic remitting pustular dermatitis but was not diagnosed 151 with psoriasis. Her skin disease continues into adulthood. Two different patients with enteropathic 152 CRMO had atopic dermatitis and nail pitting, but not skin disease corresponding to psoriasis.

153 In the next part of our study, we aimed to compare solely osteolytic and complex CRMO in children. 154 A family history of autoimmune diseases was present in 71% of children with osteolytic CRMO and in 155 65% of children with complex CRMO. No differences were found for blood markers like leukocyte and 156 platelet counts, haemoglobin, and mean cell volume (MCV) (Fig. 4A). By contrast, inflammatory 157 activity was significantly higher in complex than in osteolytic disease (CRP, p=0.018; ESR, p=0.0064; 158 Fig. 4B). Children with osteolytic CRMO manifested disease slightly earlier (mean 105 ± 36 months) 159 than did children with complex CRMO (mean 123 ± 38 months); however, the difference was 160 statistically not significant (p=0.1336). Nor did the number of lesions differ between the two groups 161 (Fig. 4B). Interestingly, we found statistically significant differences in affected sites between the two 162 groups. Whereas children with osteolytic CRMO often displayed long-bone involvement, children with 163 complex CRMO presented predominantly with involvement of clavicle and pelvis (clavicle, p=0.011; pelvis, p=0.038; Fig. 5). Frequent and almost equal between both patient groups was femoral (50% in 164 osteolytic CRMO, 48% in complex CRMO) and spinal involvement (43% in osteolytic CRMO, 35% in 165 complex CRMO; see also Tab. 3). 166

167 Treatment options used in our cohort are summarized in Fig. 6. All children with osteolytic CRMO and 168 74% of those with complex CRMO received NSAIDs, including ibuprofen, naproxen, or diclofenac. Half 169 of the patients were treated with bisphosphonates (pamidronate or zoledronate) because of spinal 170 involvement or inefficacy of NSAIDs. The percentage of bisphosphonate treatment was similar for the 171 osteolytic and complex CRMO groups (respectively 43% and 50%), while spinal involvement was identified in respectively 43% and 35% of children. Children with complex CRMO more often received 172 conventional synthetic DMARDs, corticosteroids, and biologic therapy (TNFi) (Fig. 6). Substantial 173 174 improvement or disease remission was achieved in 27 patients (73%); 7 children (19%) still have active 175 chronic or remittent disease. Three patients with complex CRMO were lost to follow-up due to non-176 compliance.

### 177 Discussion

178 In this study, we focused on different phenotypes of CRMO. We observed that children with 179 extraosseous involvement present with significantly increased inflammatory activity, have a distinct 180 type of bone involvement, and more frequently require escalation to a second-line therapy. No 181 differences in number of bone lesions and in age at disease onset were found.

Some earlier studies noticed phenotypic differences between CRMO patients and endeavoured to 182 183 stratify their patients according to severity and disease course <sup>7,17,25</sup>. Wippf et al. defined three 184 subgroups of CRMO patients <sup>7</sup>. Compared to the mild form, children with intermediate and severe phenotypes more frequently presented with extraskeletal co-morbidities, multifocal disease, and 185 inflammatory syndrome. The more aggressive CRMO phenotype, with higher rates of multifocality, 186 higher ESR, and predominant involvement of feet, tibia, pelvis, and humerus was described in children 187 188 with extraosseous manifestation by Borzutzky and colleagues <sup>6</sup>. In accordance with these findings, 189 O'Leary et al. demonstrated multifocality of lesions and low response rate to NSAIDs in their Irish 190 cohort with a high prevalence of extraosseous involvement. We observed similar differences between 191 children with and without extraosseous manifestations. Our findings further suggest that lesions in 192 complex CRMO patients with affected extraskeletal tissues, particularly skin, gut, and joints, are 193 differently distributed. Clavicular and pelvic lesions dominated in complex CRMO whereas lesions in 194 metaphysis of long bones and foot were less frequent (Fig. 5B). On the contrary, foot and long bones, 195 specifically tibia, were prevalent sites of lesions in osteolytic CRMO. In our group of patients, we 196 noticed an unusually high incidence of IBD compared with other cohorts. In the subgroup of patients 197 with IBD, the dominant osteolytic pattern comprises clavicle and pelvis. However, further studies on 198 a large cohort are required for generalisation of our observations and determination of predictive 199 value of lesion distribution in CRMO subtypes.

200 Family history has an important, yet not fully understood role in CRMO. More than 50% of children in 201 reported cohorts had family histories of autoimmune disorders, especially of those on the 202 spondyloarthritis spectrum. One of the characteristics of these disorders, recently extensively studied, 203 is the alteration of gut homeostasis and of the enterobiome. Extraosseous manifestations observed in our patients and autoimmune diseases in families exhibit similarities (Fig. 2). Arthritis, IBD, and 204 205 psoriasis are conditions shared between the two groups. However, specific autoimmune diseases are 206 not clustered within the families in any apparent pattern. For example, only half of the children with 207 enteropathic CRMO in our cohort have a family history of IBD. On the other hand, arthritis or psoriasis, 208 also present in pedigrees of our patients, is known to be associated with alteration of gut microbiota 209 <sup>26-29</sup>. Thus, it can represent an additional factor contributing to the development of enteropathic CRMO. Indeed, such correlation was proposed in two CRMO studies <sup>27, 30</sup>. A recent report also 210 211 describes successful deployment of a Crohn- disease exclusion diet in a paediatric patient with 212 enteropathic CRMO <sup>31</sup>. Interestingly, we observed elevated FCP levels in 31% of our patients with 213 active CRMO (apart from those with the enteropathic form), indicating the presence of subclinical gut 214 inflammation. The retrospective character of this study prevented analysis of the microbiome in our 215 patients. Nevertheless, a better understanding of the interplay between genetic predispositions, 216 mirrored in family history of the probands, and environmental factors could promote our understanding of disease aetiopathogenesis and possibly shape future therapy strategies. A possible 217 218 inference is that children with a higher risk of IBD may profit from an earlier switch to TNFi or from 219 NSAIDs avoidance. Similarly, to identify patients at high risk for development of psoriasis, including 220 paradoxical disease during TNFi treatment, could encourage concomitant treatment with DMARDS, such as methotrexate <sup>32,33</sup>. 221

222 Even though our study has yielded several interesting findings, we must mention limitations that 223 restrain us from offering general recommendations. First and foremost, the number of children with 224 CRMO in this cohort is low. The retrospective approach in this study did not allow implementation of a uniform treatment protocol for all patients and a comprehensive evaluation of the treatment 225 226 response. Importantly, our findings are in line with other studies indicating that CRMO is a 227 heterogeneous disease <sup>34,35</sup> and that "CMRO" might be considered as an umbrella term for 228 phenotypically similar disorders with potentially diverse etiopathogenetic backgrounds and sterile 229 osteomyelitis as a dominant feature.

- In conclusion, osteomyelitis as a dominant phenotypic feature of CRMO is accompanied by inflammation of other tissues in a substantial group of patients. The disease thus presents in two main forms, osteolytic and complex. The concept of CRMO as a clinical continuum between these two distinctive forms impedes definition of diagnostic and therapeutic strategies. A tailored therapy of CRMO patients remains unavailable. However, a detailed clinical stratification of patients followed by genetic-epigenetic studies can promote early identification of high-risk patients, who could benefit
- 236 from more aggressive treatment with early therapy escalation.

### 237 Availability of data and materials

- 238 The datasets used and/or analysed during the current study are available from the corresponding
- author on reasonable request.
- 240 Abbreviations
- 241 CNO chronic non-bacterial osteomyelitis
- 242 CRMO chronic recurrent multifocal osteomyelitis
- 243 CRP C-reactive protein
- 244 DIRA deficiency of interleukin-1 receptor antagonist
- 245 DMARD disease-modifying anti-rheumatic drug
- 246 FCP foetal calprotectin
- 247 HLA human leukocyte antigen
- 248 IBD inflammatory bowel disease

- 249 MRI magnetic resonance imaging
- 250 NSAID non-steroidal anti-inflammatory drug
- 251 SAPHO synovitis, acne, pustulosis, hyperostosis, osteitis
- 252 TNFi tumour necrosis factor inhibitor
- 253 WB-MRI whole-body MRI

### References

- 1. Bjorksten, B., Gustavson, K.H., Eriksson, B., Lindholm, A. & Nordstrom, S. Chronic recurrent multifocal osteomyelitis and pustulosis palmoplantaris. *J Pediatr* **93**, 227-31 (1978).
- 2. Giedion, A. Subacute and chronic "symmetrical" osteomyeliti. *Ann Radiol (Paris)* **15**, 329-342 (1972).
- 3. Jansson, A.F., Grote, V. & Group, E.S. Nonbacterial osteitis in children: data of a German Incidence Surveillance Study. *Acta Paediatr* **100**, 1150-7 (2011).
- 4. Zhao, Y. & Ferguson, P.J. Chronic Nonbacterial Osteomyelitis and Chronic Recurrent Multifocal Osteomyelitis in children. *Pediatr Clin North Am* **65**, 783-800 (2018).
- 5. Andronikou, S. et al. Whole-body MRI in the diagnosis of paediatric CNO/CRMO. *Rheumatology (Oxford)* **59**, 2671-2680 (2020).
- 6. Borzutzky, A. et al. Pediatric chronic nonbacterial osteomyelitis. *Pediatrics* **130**, e1190-7 (2012).
- 7. Wipff, J. et al. A large national cohort of French patients with chronic recurrent multifocal osteitis. *Arthritis Rheumatol* **67**, 1128-37 (2015).
- 8. O'Leary, D., Wilson, A.G., MacDermott, E.J., Lowry, C. & Killeen, O.G. Variability in phenotype and response to treatment in chronic nonbacterial osteomyelitis; the Irish experience of a national cohort. *Pediatr Rheumatol Online J* **19**, 45 (2021).
- 9. Girschick, H. et al. The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. *Rheumatology* (*Oxford*) **57**, 1203-1211 (2018).
- 10. Zhao, Y. et al. Consensus treatment plans for Chronic Nonbacterial Osteomyelitis refractory to Nonsteroidal Antiinflammatory Drugs and/or with active spinal lesions. *Arthritis Care Res* (*Hoboken*) **70**, 1228-1237 (2018).
- 11. Cox, A.J. et al. Recessive coding and regulatory mutations in FBLIM1 underlie the pathogenesis of chronic recurrent multifocal osteomyelitis (CRMO). *PLoS One* **12**, e0169687 (2017).
- 12. d'Adamo, A.P. et al. High prevalence of rare FBLIM1 gene variants in an Italian cohort of patients with Chronic Non-bacterial Osteomyelitis (CNO). *Pediatr Rheumatol Online J* **18**, 55 (2020).
- 13. Ferguson, P.J. et al. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). *J Med Genet* **42**, 551-7 (2005).
- 14. Aksentijevich, I. et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. *N Engl J Med* **360**, 2426-37 (2009).
- 15. https://omim.org/.
- 16. Vittecoq, O. et al. Evolution of chronic recurrent multifocal osteitis toward spondylarthropathy over the long term. *Arthritis Rheum* **43**, 109-19 (2000).
- 17. Jansson, A. et al. Classification of non-bacterial osteitis: retrospective study of clinical, immunological and genetic aspects in 89 patients. *Rheumatology (Oxford)* **46**, 154-60 (2007).
- 18. Beck, C. et al. Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment. *Arthritis Res Ther* **12**, R74 (2010).
- 19. Kostik, M.M., Kopchak, O.L., Chikova, I.A., Isupova, E.A. & Mushkin, A.Y. Comparison of different treatment approaches of pediatric chronic non-bacterial osteomyelitis. *Rheumatol Int* **39**, 89-96 (2019).
- 20. Schnabel, A., Range, U., Hahn, G., Berner, R. & Hedrich, C.M. Treatment response and longterm outcomes in children with Chronic Nonbacterial Osteomyelitis. *J Rheumatol* **44**, 1058-1065 (2017).

- 21. Dushnicky, M.J. et al. Pediatric patients with a dual diagnosis of Inflammatory Bowel Disease and Chronic Recurrent Multifocal Osteomyelitis. *J Pediatr Gastroenterol Nutr* **73**, 626-629 (2021).
- 22. Sag, E. et al. Chronic recurrent multifocal osteomyelitis in children: a single center experience over five years. *Turk J Pediatr* **61**, 386-391 (2019).
- 23. Roderick, M.R., Shah, R., Rogers, V., Finn, A. & Ramanan, A.V. Chronic recurrent multifocal osteomyelitis (CRMO) advancing the diagnosis. *Pediatr Rheumatol Online J* **14**, 47 (2016).
- 24. Khan, M.A. HLA-B27 and its subtypes in world populations. *Curr Opin Rheumatol* **7**, 263-9 (1995).
- 25. Chamot, A.M. et al. [Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases]. *Rev Rhum Mal Osteoartic* **54**, 187-96 (1987).
- 26. Gracey, E. et al. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. *Nat Rev Rheumatol* **16**, 415-433 (2020).
- 27. Zhao, D.Y., McCann, L., Hahn, G. & Hedrich, C.M. Chronic nonbacterial osteomyelitis (CNO) and chronic recurrent multifocal osteomyelitis (CRMO). *J Transl Autoimmun* **4**, 100095 (2021).
- 28. Myers, B. et al. The gut microbiome in psoriasis and psoriatic arthritis. *Best Pract Res Clin Rheumatol* **33**, 101494 (2019).
- 29. Verwoerd, A., Ter Haar, N.M., de Roock, S., Vastert, S.J. & Bogaert, D. The human microbiome and juvenile idiopathic arthritis. *Pediatr Rheumatol Online J* **14**, 55 (2016).
- 30. Ter Horst, R. et al. Host and environmental factors influencing individual human cytokine responses. *Cell* **167**, 1111-1124 e13 (2016).
- 31. Cantarelli, E., Baccelli, F., Simonini, G. & Alvisi, P. Chronic Recurrent Multifocal Osteomyelitis associated with Crohn Disease: A potential role of exclusion diet? Comment on Starz et al. The Modification of the gut microbiota via selected specific diets in patients with Crohn's Disease. Nutrients 2021, 13, 2125. *Nutrients* **13**(2021).
- 32. Pugliese, D. et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. *Aliment Pharmacol Ther* **42**, 880-8 (2015).
- 33. Rosenwasser, N., Lee, D., Sidbury, R. & Zhao, Y. Paradoxical Psoriasis in children receiving anti-TNFalpha treatment for inflammatory/autoimmune disease. *Paediatr Drugs* **23**, 131-141 (2021).
- 34. Prakken, B., Albani, S. & Martini, A. Juvenile idiopathic arthritis. *Lancet* **377**, 2138-49 (2011).
- 35. Thatayatikom, A., Modica, R. & De Leucio, A. Juvenile Idiopathic Arthritis. in *StatPearls* (Treasure Island (FL), 2022).

### Acknowledgement

We would like to thank A. S. Knisely (Med Univ Graz, Austria) for critical comments and revision of the manuscript.

### Funding

This study was supported by a grant from the Czech Health Research Council, Ministry of Health, Czech Republic (NU20-05-00320) and Ministry of Health, Czech Republic – conceptual development of research organization, Motol University Hospital, Prague, Czech Republic (00064203). MC and ZK were funded by Czech Science Foundation (19-0704S).

### Author information

### Contributions

DC designed the study, provided patient information and wrote the manuscript, HM provided patient information and reviewed manuscript, VK re-assessed X-ray and WBMR imaging and reviewed manuscript, ZK performed statistical analyses, OS contributed to data analyses and reviewed the manuscript, LW provided patient data and reviewed the manuscript, JB contributed to data analyses and reviewed the manuscript, ZŠ contributed to data analyses and reviewed the manuscript, MK re-assessed X-ray and WBMR imaging, provided WBMR pictures for Fig. 5B and reviewed manuscript, MC contributed to the critical revisions of manuscript, data analyses and prepared the figures and tables, RH contributed to data analyses and reviewed the manuscript. All authors agreed with final version of the manuscript.

### Corresponding author

Correspondence to Dita Cebecauerova ( <u>Dita.Cebecauerova@fnmotol.cz</u> ).

### Ethics declarations

### Ethics approval and consent to participate

All participants or their legal guardians gave written consent in participating in the study. The study was performed as an retrospective cohort study according to the principles of the Declaration of Helsinki and was approved by the local ethics committee at the University Hospital Motol (protocol No. EK 1412/20).

### Figure legends

**Figure 1. A graphical scheme summarising critical findings in our cohort.** CRP – C-reactive protein, DMARD - disease-modifying antirheumatic drugs, ESR - erythrocyte sedimentation rate, IBD – inflammatory bowel disease, NSAID - non-steroidal anti-inflammatory drugs, TNFi – tumour necrosis factor  $\alpha$  inhibitors.

**Figure 2. Autoimmunity profiles. A)** Summary of total autoimmune disease manifestations in the first- and second-degree relatives and of **B)** extraosseous comorbidities in CRMO patients. CGD – chronic granulomatous disease, GPA – granulomatosis with polyangiitis, HSP – Henoch-Schönlein purpura, IBD – inflammatory bowel disease, PD – phagocytic dysfunction, PPP – palmoplantar pustulosis, PSC – primary biliary cirrhosis RA – rheumatoid arthritis

**Figure 3. Vertebral and sacroiliac involvement.** HLA-B27 positive children with CRMO displayed sacroiliac involvement less frequently than spinal involvement. Vertebral lesions were twice as frequent as in the cohort. Sacroiliitis in HLA-B27 positive CRMO was less frequent than sacroiliitis in HLA-B27 negative CRMO children and in non-selected CRMO children.

**Figure 4. Comparison of laboratory characteristics between osteolytic and complex CRMO patients. A.** Charts comparing blood markers, white blood count, platelets, haemoglobin, and mean cell volume (MCV) for the two groups of CRMO patients. Data are presented as boxplots with the 25th, 50th (median), and 75th percentiles marked. Whiskers extend to the most extreme data points. Squares represent individual patients. An asterisk (\*) indicates statistical significance (p<0.05). **B.** Comparison of inflammatory markers, number of lesions, and age at onset between osteolytic and complex CRMO. Data are presented as boxplots with the 25th, 50th (median), and 75th percentiles marked. Whiskers extend to the most extreme data points. Squares represent individual patients. An asterisk (\*) indicate statistical significance (p<0.05 and p<0.01, respectively).

**Figure 5. Distribution of CRMO lesions in osteolytic CMRO patients (left) and complex CRMO patients (right). A.** Frequencies ≥ 35% are considered important (bold). P-values for each site are summarized in Table 3. **B.** Dominant patterns (red) of affected bones in osteolytic CMRO (left) and complex CRMO (right) with illustrative cases of WB-MRI. Arrowheads indicate main affected sites.

**Figure 6. Treatments applied in patients with osteolytic (dark grey) and complex (light grey) CRMO.** NSAID - non-steroidal anti-inflammatory drugs, DMARDs – disease modifying antirheumatic drugs, CS – corticosteroids, BIS – bisphosphonates, TNFi – tumour necrosis factor α inhibitors

Tables

### Table 1. Demographic and clinical characteristics of the cohort

Total number of patients	37					
Female	30 (81%)					
Male	7 (19%)					
Ethnicity						
- Romani	4 (11%)					
- Other Czech	33 (89%)					
Age at onset, years; median (range)	10 (4.6 – 17.3)					
Number of lesions; median (range)	7 (1-19)					
Skeletal involvement						
- Unifocal	3 (8%)					
- Multifocal	34 (92%)					
Initial symptom						
- Back pain	14 (38%)					
- Limb pain	19 (51%)					
- Other	4 (11%)					
Bone biopsy	23 (62%)					
Spinal lesions	14 (38%)					
- Spinal surgery	7 (19%)					
Sacroiliac joint involvement	13 (35%)					
Inflammatory bowel disease	8 (22%)					
Psoriasis / palmoplantar pustulosis	3 (8%)					
Nodulocystic acne	3 (8%)					
Unspecific dermatitis involvement	3 (8%)					
Autoimmune comorbidities in family history	25 (68%)					
- First-degree (I) relatives	15					
- Second-degree (II) relatives	13					
Anti-nuclear antibodies present	2 (5%)					
HLA-B27 present	6 (16%)					

No.	Gender	No. foci	Autoantibodies	Histology	Disease course	Delay (years)	Therapy	Outcome	HLA- B27	FCP (µg/g)	Family history
1.	F	7	ASCA positive	NS colitis	1. CRMO, arthritis 2. colitis + CRMO relapse	5.0	SSZ> P >ADA+MTX> none	remission, now without therapy	negative	1000	II. HLA-B27 AS
2.	Μ	10	p-ANCA positive	CD	1. IBD 2. PPP 3. CRMO + IBD relapse	4.0	AZA, IFX, IFX+MTX >ADA	relapsing IBD and CRMO	negative	1736	I. IBD
3.	F	2	ASCA positive	CD	1. CRMO, arthritis 2. IBD 3. HSP 4. acute uveitis	0.5	SSZ> ETA+MTX> ADA, AZA	remission on therapy	positive	350	I. IBD
4.	F	9	ASCA positive	CD	1. IBD 2. CRMO+PPP	4.0	AZA>IFX>ADA >ADA+SSZ >ADA+MTX+SSZ	remission on therapy	negative	3329	II. psoriasis
5.	F	3	p-ANCA positive	UC	1. IBD 2. relapsed IBD+CRMO	2.5	P+AZA>5-ASA >ADA+MTX	remission on therapy	negative	938	negative
6.	F	11	negative	UC, PSC	1. IBD, PSC 2. CRMO	4.0	5-ASA, UDCA, PAM- ->ADA	active CRMO, IBD in remission	negative	1680	II. IBD
7.	М	7	p-ANCA positive	CD	1. CRMO, arthritis 2. IBD (arthritis and CRMO in remission)	7.5	NSAID> SSZ, P, MTX> ADA	active IBD, CRMO in remission	negative	1230	unknown
8.	Μ	9	negative	CD	1. CRMO 2. IBD (CRMO in remission)	4.0	NSAID> P>5-ASA- ->non-compliance	active IBD, CRMO in remission	negative	545	I. IBD, II. psoriasis

 Table 2. Characteristics of patients with enteropathic chronic recurrent multifocal osteomyelitis

<u>Abbreviations:</u> ADA – adalimumab, ANCA – anti-neutrophil cytoplasmic antibody, ASCA – anti-*Saccharomyces cerevisiae* antibody, 5-ASA – 5-aminosalicylic acid, AZA – azathioprine, CD – Crohn disease, CRMO – chronic recurrent multifocal osteomyelitis, ETA – etanercept, FCP – foetal calprotectin, I. – first-degree relative, II. – second-degree relative, HLA-B27 – human leucocyte antigen B27, HLA-B27 AS – HLA-B27 positive ankylosing spondylitis, IBD – inflammatory bowel disease, IFX – infliximab, MTX – methotrexate, NS colitis – non-specific colitis, NSAID – non-steroidal anti-inflammatory drug, P – prednisone, PAM – pamidronate, PPP – palmo-plantar pustulosis, PSC – primary sclerosing cholangitis, SSZ – sulphasalazine, UC – ulcerative colitis, UDCA – ursodeoxycholic acid.

Affected site	Osteolytic CRMO (no = 14)	Complex CRMO (n = 23)	P value
skull	1	1	1.000
mandible	2	0	0.137
scapula	1	1	1.000
clavicle	1	12	0.011
sternum	1	6	0.217
humerus	5	3	0.215
radius	3	3	0.653
ribs	3	2	0.346
spine	6	8	0.732
pelvis (incl. sacrum)	5	17	0.038
femur	7	11	1.000
tibia	9	7	0.086
fibula	2	3	1.000
talus	2	3	1.000
calcaneus	4	2	0.173
feet with digits	7	6	0.171

### Table 3. Distribution of lesions in patients with osteolytic and complex CRMO



Cebecauerova Figure 1



**Extraosseous** manifestations

Cebecauerova Figure 2

В



## Cebecauerova Figure 3



Cebecauerova Figure 4A



Cebecauerova Figure 4B

# Osteolytic CRMO (14 patients)

# Complex CRMO (23 patients)



Cebecauerova Figure 5A







Cebecauerova Figure 5B



# Cebecauerova Figure 6